<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519113</url>
  </required_header>
  <id_info>
    <org_study_id>GC1102_P2b/3</org_study_id>
    <nct_id>NCT03519113</nct_id>
  </id_info>
  <brief_title>HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102</brief_title>
  <official_title>Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluated the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study for GC1102 to demonstrate preventing the recurrence of hepatitis B
      virus (HBV) infection following liver transplantation and a dose-finding study to determine
      its optional dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GC1102 is a new recombinant hepatitis B immunoglobulin (HBIG) from Chinese Hamster Ovary
      (CHO) cells. It is a monoclonal antibody and has high affinity and avidity to hepatitis B
      surface antigen and several advantages compared to HBIG derived from blood plasma of human
      donors. Volunteers will participate in the study, receive 24-week treatment with
      80,000/100,000 IU of GC1102 or I.V HBIG and be followed up till 28 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention Failure rate of HBV</measure>
    <time_frame>28weeks</time_frame>
    <description>Seroconversion rate of HBsAg or HBeAg, anti-HBs &lt; 500 IU/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of HBV</measure>
    <time_frame>28weeks</time_frame>
    <description>Seroconversion rate of HBsAg or HBeAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prophylactic failure rate of HBV</measure>
    <time_frame>28weeks</time_frame>
    <description>Seroconversion rate of HBsAg or HBeAg, anti-HBs &lt; 500 IU/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence duration</measure>
    <time_frame>28weeks</time_frame>
    <description>Seroconversion time of HBsAg or HBeAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>survival rate during 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer of HBV DNA</measure>
    <time_frame>1 year</time_frame>
    <description>Geometric mean titer(GMT) of HBV DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of anti-HBe</measure>
    <time_frame>1 year</time_frame>
    <description>anti-hepatitis B e(HBe)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic(PK) parameters</measure>
    <time_frame>1 year</time_frame>
    <description>serum drug titer</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under curve(AUC)</measure>
    <time_frame>1 year</time_frame>
    <description>area under the baseline corrected serum titer versus time curve from time 0 to time of the last measureable titer</description>
  </other_outcome>
  <other_outcome>
    <measure>clearance(CL)</measure>
    <time_frame>1 year</time_frame>
    <description>clearance</description>
  </other_outcome>
  <other_outcome>
    <measure>Vdss</measure>
    <time_frame>1 year</time_frame>
    <description>volume of distribution</description>
  </other_outcome>
  <other_outcome>
    <measure>Vdss/CL</measure>
    <time_frame>1 year</time_frame>
    <description>effective half-life</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events occured during clinical trials</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical abnormalities</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical laboratory test</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Hepatitis B Infection</condition>
  <arm_group>
    <arm_group_label>Test group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 80,000 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GC1102 100,000 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>I.V HBIG</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1102 80,000 IU</intervention_name>
    <description>recombinant human hepatitis B immunoglobulin</description>
    <arm_group_label>Test group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1102 100,000 IU</intervention_name>
    <description>recombinant human hepatitis B immunoglobulin</description>
    <arm_group_label>Test group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>I.V HBIG</intervention_name>
    <description>human anti-hepatitis B Immunoglobulin</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject who was informed of, and fully understood, all aspects of the study and has
             provided voluntary written consent for participation in the study

          2. Subject aged over 19 years at the time of consent provided

          3. Subject with planned liver transplantation due to HBV-related end-stage liver disease
             such as cirrhosis, liver cancer and fulminant hepatic failure

          4. Subject with HBsAg(+)

        Exclusion Criteria:

          1. Subject with planned reoperation following liver transplantation

          2. Subject with hemophilia

          3. Subject with a history of venous or arterial thrombosis

          4. Subject with HAV, HCV or HIV infection

          5. Subject with immunodeficiency or immunosuppression due to whole body steroids before
             liver transplantation

          6. Subject with hemolytic or blood loss anemia

          7. Subject with IgA deficiency

          8. Subject with a history of malignant tumor within the last 5 years, excluding primary
             liver cancer

          9. Subject with moderate to severe kidney disease (serum creatinine &gt; 20mg/dL or anuria,
             kidney failure or dialysis)

         10. Subject with a history of transient ischemic attack(TIA), myocardial infarction(MI),
             unstable angina, cerebral infarction, cerebral hemorrhage, percutaneous transluminal
             angioplasty(PTA) or coronary artery bypass graft(CABG) within the last 6 months prior
             to the screening

         11. Subject with severe heart failure(NYHA class III~IV), arrythmia requiring treatment

         12. Subject with known hypersensitivity (anaphylaxis) to any component of the study drug

         13. Subject who had received other immunoglobulin product within the last 3 months prior
             to the study entry

         14. Subject who had received live parenteral vaccine (MMR, Cholera and Varicella) within
             the last 3 months prior to the study entry

         15. Subject who had received estrogen or hormone alternative medicine

         16. Pregnant or breast-feeding women

         17. Woman of childbearing potential with positive pregnancy test confirmed by serum
             beta-human chorionic gonadotropin(B-HCG) test within 28 days prior to dosing by urine
             pregnancy or Subject who refused to use a reliable method of contraception

         18. Alcohol or drug abuse within 6 months

         19. Subject who has participated in any other clinical trial within 30 days

         20. Subject who has any clinically meaningful disease investigator's judgement to prevent
             participating in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Gyu Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohye Yun</last_name>
    <phone>031-260-0866</phone>
    <email>ysh@greencross.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-Gyu Lee, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV-related liver transplantation</keyword>
  <keyword>Hepatitis B immunoglobulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

